Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 47 results for "Indolent B-Cell Lymphoma (IBCL)".

Thumbnail for Life Expectancy of Hairy Cell Leukemia Patients Approaches General Population: An Updated Analysis of 5669 Cases from SEER Database (1978-2020)

IBCL - 1715

Life Expectancy of Hairy Cell Leukemia Patients Approaches General Population: An Updated Analysis of 5669 Cases from SEER Database (1978-2020)

Alamin Mustafa

Poster Presenter: Alamin Mustafa

Thumbnail for Real-World Outcomes of Bendamustine & Rituximab With or Without Maintenance Rituximab in Follicular Lymphoma: A TriNetX Analysis

IBCL - 1764

Real-World Outcomes of Bendamustine & Rituximab With or Without Maintenance Rituximab in Follicular Lymphoma: A TriNetX Analysis

Anuja Abhyankar

Poster Presenter: Anuja Abhyankar

Previous 1 2 3 4 5 6 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Noncancer Competing Mortality in Follicular Lymphoma: Cardiovascular, Infectious, and Second Malignancy Deaths in a Population-Based Cohort, SEER 2000-2022

IBCL - 184

Noncancer Competing Mortality in Follicular Lymphoma: Cardiovascular, Infectious, and Second Malignancy Deaths in a Population-Based Cohort, SEER 2000-2022

Yasir Aziz

Poster Presenter: Yasir Aziz

$Thumbnail for Treatment Preferences and Perceived Barriers to Epcoritamab Plus Rituximab and Lenalidomide in Relapsed/Refractory Follicular Lymphoma: A Real-World Survey of US Hematologists/Oncologists$

IBCL - 236

Treatment Preferences and Perceived Barriers to Epcoritamab Plus Rituximab and Lenalidomide in Relapsed/Refractory Follicular Lymphoma: A Real-World Survey of US Hematologists/Oncologists

Blaise Nwotchouang

Poster Presenter: Blaise Nwotchouang

Thumbnail for Light Chain Amyloidosis in Waldenstrφm Macroglobulinemia/Lymphoplasmacytic Lymphoma: Treatment Strategies and Outcomes of 74 Cases

IBCL - 290

Light Chain Amyloidosis in Waldenstrφm Macroglobulinemia/Lymphoplasmacytic Lymphoma: Treatment Strategies and Outcomes of 74 Cases

Nicol? Danesin

Poster Presenter: Nicol? Danesin

Thumbnail for Patterns of Treatment Utilization and Sequencing Across Lines of Therapy in Waldenstrφm Macroglobulinemia: Real-World Evidence From the United States

IBCL - 291

Patterns of Treatment Utilization and Sequencing Across Lines of Therapy in Waldenstrφm Macroglobulinemia: Real-World Evidence From the United States

Jorge J Castillo

Poster Presenter: Jorge J Castillo

Thumbnail for CD10 Loss Defines a Biologically Distinct and Extranodal-Enriched Subset of Follicular Lymphoma: A Systematic Review and Meta-Analysis

IBCL - 293

CD10 Loss Defines a Biologically Distinct and Extranodal-Enriched Subset of Follicular Lymphoma: A Systematic Review and Meta-Analysis

Adarsh Vardhan Tangella

Poster Presenter: Adarsh Vardhan Tangella

Thumbnail for Relapse-Mortality Trade-off Between Autologous and Allogeneic Stem Cell Transplantation in Relapsed Follicular lymphoma and Marginal zone lymphoma: A Registry-Based Proportional Meta-Analysis

IBCL - 295

Relapse-Mortality Trade-off Between Autologous and Allogeneic Stem Cell Transplantation in Relapsed Follicular lymphoma and Marginal zone lymphoma: A Registry-Based Proportional Meta-Analysis

Adarsh Vardhan Tangella

Poster Presenter: Adarsh Vardhan Tangella

Thumbnail for Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis

IBCL - 334

Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis

Wenny Lin

Poster Presenter: Wenny Lin

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors